State of the art paper
The role of nateglinide and repaglinide, derivatives of meglitinide, in the treatment of type 2 diabetes mellitus
 
More details
Hide details
 
Submission date: 2012-11-13
 
 
Final revision date: 2013-01-04
 
 
Acceptance date: 2013-01-31
 
 
Online publication date: 2013-04-30
 
 
Publication date: 2013-10-31
 
 
Arch Med Sci 2013;9(5):936-943
 
KEYWORDS
TOPICS
ABSTRACT
Type 2 diabetes mellitus (T2DM) is one of the most common chronic diseases worldwide, presenting a great challenge to the public health systems due to high morbidity and mortality, because of frequent micro-/macro-vascular complications. Many treatment options are now available, with different efficacy as well as mechanisms of action to improve deranged glucose metabolism. We review some of the available data on derivatives of meglitinide, namely nateglinide and repaglinide. These two compounds increase insulin secretion by a mechanism similar to the one of sulfonylureas, but with a shorter half-life. Nateglinide and repaglinide, derivatives of meglitinides, have characteristic pharmacodynamic and pharmacokinetic properties that, together with their proposed mechanism of action, make them useful for type 2 diabetes mellitus, especially when used in combination therapy.
eISSN:1896-9151
ISSN:1734-1922
Journals System - logo
Scroll to top